Početna › Prekomjerna tjelesna masa › Indiana
Kliničke studije za Prekomjerna tjelesna masa u državi Indiana
16 studija za Prekomjerna tjelesna masa traži sudionike na lokacijama u državi Indiana.
Gradovi u državi Indiana
Službeni tekst studije (engleski)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- IU Health - Riley Physicians Endo-Diab, Indianapolis
U tijeku regrutacijaFaza 3
Od 8 do 18 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07253285AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Midwest Inst For Clin Res, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Midwest Inst For Clin Res, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- MediSphere Medical Research Center, LLC, Evansville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07595549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Riley Hospital for Children, Indianapolis
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- DM Clinical Research - Indianapolis, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Cardiovascular Research of Northwest Indiana LLC, Munster
- Velocity Clinical Research - Valparaiso, Valparaiso
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Qualmedica Research, LLC, Evansville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Evansville
- AURORA-1 Clinical Site, Indianapolis
- AURORA-1 Clinical Site, Valparaiso
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Evansville
- AURORA-2 Clinical Site, Indianapolis
- AURORA-2 Clinical Site, Valparaiso
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Investigators Research Group, Brownsburg
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06897475A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Midwest Inst For Clin Res, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07745504Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- Indiana University, Indianapolis
U tijeku regrutacija
Od 18 do 45 godina · Žene · Ažurirano 24. lip 2026. · NCT05124808Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.